

# Elizabeth R Graef

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/465831/publications.pdf>

Version: 2024-02-01

18  
papers

763  
citations

932766

10  
h-index

940134

16  
g-index

18  
all docs

18  
docs citations

18  
times ranked

1452  
citing authors

#	ARTICLE	IF	CITATIONS
1	Structural Evidence for Loose Linkage between Ligand Binding and Kinase Activation in the Epidermal Growth Factor Receptor. <i>Molecular and Cellular Biology</i> , 2010, 30, 5432-5443.	1.1	179
2	A Rush to Judgment? Rapid Reporting and Dissemination of Results and Its Consequences Regarding the Use of Hydroxychloroquine for COVID-19. <i>Annals of Internal Medicine</i> , 2020, 172, 819-821.	2.0	177
3	<scp>SARS</scp>â€“<scp>CoV</scp>â€“2 Infection and <scp>COVID</scp>â€“19 Outcomes in Rheumatic Diseases: A Systematic Literature Review and Metaâ€“Analysis. <i>Arthritis and Rheumatology</i> , 2022, 74, 766-775.	2.9	117
4	Baseline use of hydroxychloroquine in systemic lupus erythematosus does not preclude SARS-CoV-2 infection and severe COVID-19. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1386-1388.	0.5	67
5	Swinging the pendulum: lessons learned from public discourse concerning hydroxychloroquine and COVID-19. <i>Expert Review of Clinical Immunology</i> , 2020, 16, 659-666.	1.3	57
6	Immediate effect of the COVID-19 pandemic on patient health, health-care use, and behaviours: results from an international survey of people with rheumatic diseases. <i>Lancet Rheumatology</i> , The, 2021, 3, e707-e714.	2.2	40
7	<i>Festina lente</i>: hydroxychloroquine, COVID-19 and the role of the rheumatologist. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 734-736.	0.5	35
8	Complement and coagulation cascades in trauma. <i>Acute Medicine &amp; Surgery</i> , 2019, 6, 329-335.	0.5	31
9	Acute respiratory viral adverse events during use of antirheumatic disease therapies: A scoping review. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 1191-1201.	1.6	19
10	Inflammatory arthritis in patients with COVID-19. <i>Translational Research</i> , 2021, 232, 49-59.	2.2	19
11	The impact of COVID-19 on rheumatology trainingâ€“results from the COVID-19 Global Rheumatology Alliance trainee survey. <i>Rheumatology Advances in Practice</i> , 2022, 6, rkac001.	0.3	7
12	Rapid Adoption of Telemedicine in Rheumatology Care During the <scp>COVID</scp>â€“19 Pandemic Highlights Training and Supervision Concerns Among Rheumatology Trainees. <i>ACR Open Rheumatology</i> , 2022, 4, 128-133.	0.9	6
13	Response to: â€“Antimalarial use and arrhythmias in COVID-19 and rheumatic patients: a matter of dose and inflammation?â€™ by Erre<i>et al</i>. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, e30-e30.	0.5	4
14	Response to: â€“Correspondence on â€“<i>Festina lente</i>: hydroxychloroquine, COVID-19 and the role of the rheumatologistâ€™ by Graef<i>et al</i>â€™ by Lo<i>et al</i>. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, e164-e164.	0.5	2
15	Response to: â€“Case series of acute arthritis in COVID-19 admissionâ€™ by LÃ³pez-GonzÃ¡lez et al. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, e59-e59.	0.5	2
16	Rheumatic disease and COVID-19. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, e43-e43.	0.5	1
17	Response to: â€“Emergency arising from patientsâ€™ fear of taking antimalarials during these COVID-19 times: are antimalarials as unsafe for cardiovascular health as recent reports suggest?â€™ by Santos-Moreno<i>et al</i>. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, e155-e155.	0.5	0
18	Reply to â€“Taking a stand against the politicization of medical research: how â€“swinging the pendulumâ€“ poses a hazard to clinical trials, study participants, and the progress of scienceâ€™. <i>Expert Review of Clinical Immunology</i> , 2021, 17, 105-107.	1.3	0